HIV-1 gp41 fusion intermediate: a target for HIV therapeutics.
about
Inhibition of HIV Entry by Targeting the Envelope Transmembrane Subunit gp41.Plucking the high hanging fruit: a systematic approach for targeting protein-protein interactionsMechanism of multivalent nanoparticle encounter with HIV-1 for potency enhancement of peptide triazole virus inactivation.A novel real-time CTL assay to measure designer T-cell function against HIV Env(+) cells.Targeting HIV-1 gp41-induced fusion and pathogenesis for anti-viral therapyHIV-1 gp41 transmembrane domain interacts with the fusion peptide: implication in lipid mixing and inhibition of virus-cell fusion.The potent human immunodeficiency virus type 1 (HIV-1) entry inhibitor HR212 blocks formation of the envelope glycoprotein gp41 six-helix bundle.Cell surface assembly of HIV gp41 six-helix bundles for facile, quantitative measurements of hetero-oligomeric interactions.Roles for biological membranes in regulating human immunodeficiency virus replication and progress in the development of HIV therapeutics that target lipid metabolism.Amphipathic properties of HIV-1 gp41 fusion inhibitors.Targets for inhibition of HIV replication: entry, enzyme action, release and maturation.Computer-Aided Approaches for Targeting HIVgp41.Anti-HIV-1 Activity Prediction of Novel Gp41 Inhibitors Using Structure-Based Virtual Screening and Molecular Dynamics Simulation.Mutations of Gln64 in the HIV-1 gp41 N-terminal heptad repeat render viruses resistant to peptide HIV fusion inhibitors targeting the gp41 pocket.Effect of amphipathic HIV fusion inhibitor peptides on POPC and POPC/cholesterol membrane properties: a molecular simulation study.HIV-1 gp41 ectodomain enhances Cryptococcus neoformans binding to human brain microvascular endothelial cells via gp41 core-induced membrane activities.Development of peptide inhibitors of HIV transmission.Cationic liposomes are possible drug-delivery systems for HIV fusion inhibitor sifuvirtideHIV vs. HIV: Turning HIV-Derived Peptides into Drugs
P2860
Q34517381-0A5B0F1F-3590-4077-BD6D-FBCB90201DE6Q34522767-26BEFCEC-CF43-4AE7-8302-C7DDE9DC43D9Q34801630-8170576B-1C06-42FC-B2D0-2B5E89D940AFQ35052987-7EF38351-D9C5-4C3E-B2A9-46C14E07D7CAQ35615810-59324377-8006-4B1A-B31E-A85102044CB0Q35909307-88793E40-0206-4D4A-8BC4-B32CF87FB81DQ36634815-BFC7F955-D42A-4489-B13F-F7061F1AA905Q37065151-0555B248-FDB8-4135-8646-D37A23D39698Q37858901-38BCF005-F775-44BF-89F4-A052733B3128Q37951610-D83830C9-E11D-43C7-834A-4231B5690AB7Q37979697-A660683A-3C38-415A-B114-938ACB8623C2Q38111393-B2335F98-23CB-4219-98B7-47D31081CFB6Q39300262-A3F529EA-31E7-47B7-8262-89DC47856F14Q39455561-CFA3B7D7-49DC-457D-88AF-868C2660405AQ41770502-35A22AF1-9022-4C61-AE87-02A32984BFAFQ46779182-A407753A-78C0-444F-83CD-E14E2B9FF6F3Q55317261-9B5809E5-8DD1-4987-9669-0D38F3217E8DQ57080724-835D60FA-F80E-4117-B1B0-0FCEDA8E8617Q58626543-5D4C9A1D-0090-492A-8DB1-5458D524CF46
P2860
HIV-1 gp41 fusion intermediate: a target for HIV therapeutics.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on February 2010
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
HIV-1 gp41 fusion intermediate: a target for HIV therapeutics.
@en
HIV-1 gp41 fusion intermediate: a target for HIV therapeutics.
@nl
type
label
HIV-1 gp41 fusion intermediate: a target for HIV therapeutics.
@en
HIV-1 gp41 fusion intermediate: a target for HIV therapeutics.
@nl
prefLabel
HIV-1 gp41 fusion intermediate: a target for HIV therapeutics.
@en
HIV-1 gp41 fusion intermediate: a target for HIV therapeutics.
@nl
P1476
HIV-1 gp41 fusion intermediate: a target for HIV therapeutics.
@en
P2093
Chungen Pan
Shuwen Liu
P304
P356
10.1016/S0929-6646(10)60029-0
P50
P577
2010-02-01T00:00:00Z